About 3,395 results

ALLMedicine™ Hyperbilirubinemia Center

Research & Reviews  1,180 results

Hemolysis in Early Infancy: Still a Cause of Cholestatic Neonatal Giant Cell Hepatitis.
The American Journal of Surgical Pathology; Wu H, Tugal O et. al.

Dec 3rd, 2021 - Before the prophylactic use of anti-D antibodies in pregnancy, hemolytic anemia of the newborn was the most common cause of hyperbilirubinemia. Nowadays, given the rarity of hemolytic anemia of the newborn, hepatobiliary abnormalities, perinatal i...

Clinical Implications for Children Developing Direct Hyperbilirubinemia on Extracorpore...
Journal of Pediatric Gastroenterology and Nutrition; Alexander E, O'Sullivan D et. al.

Dec 3rd, 2021 - Extracorporeal membrane oxygenation (ECMO)-associated direct hyperbilirubinemia (DHB) is likely multifactorial. The objective of this study is to assess the frequency and risk factors for developing direct hyperbilirubinemia while on ECMO, and its...

The Influence of Diabetes on Labor Induction with Dinoprostone Vaginal Inserts.
American Journal of Perinatology; Duffy JY, Chau C et. al.

Dec 3rd, 2021 - The aim of this study was to compare duration of labor induction between diabetic and nondiabetic women receiving dinoprostone vaginal insert (10 mg). This is a secondary analysis of two large randomized controlled trials using dinoprostone vagina...

Positive direct antiglobulin test: is it a risk factor for significant hyperbilirubinem...
American Journal of Perinatology; Ercin S, Coskun Y et. al.

Dec 1st, 2021 - ABO incompatibility is a common cause of neonatal indirect hyperbilirubinemia. The direct antiglobulin test (DAT) can identify infants developing hemolytic disease. This study aims to evaluate the significance of DAT positivity among neonates with...

Maternal exposure to air pollution may increase the risk of hyperbilirubinemia in her n...
The Journal of Pediatrics; Nelin T, Burris HH

Nov 29th, 2021 - Maternal exposure to air pollution may increase the risk of hyperbilirubinemia in her newborn.|2021|Nelin T,Burris HH,|

see more →

Guidelines  3 results

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Ata...
Clinical Pharmacology and Therapeutics; Gammal RS, Court MH et. al.

Sep 30th, 2015 - The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can c...

Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or ...
Pediatrics Bhutani VK, et. al.

Sep 29th, 2011 - To standardize the use of phototherapy consistent with the American Academy of Pediatrics clinical practice guideline for the management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Relevant literature was reviewed. P...

Universal screening for hyperbilirubinemia.
Nursing for Women's Health;

Feb 9th, 2010 - Universal screening for hyperbilirubinemia.|2010||blood,blood,diagnosis,standards,

see more →

Drugs  32 results see all →

Clinicaltrials.gov  31 results

Assessment of Neonatal Hyperbilirubinemia by NeoprediX B.1 Algorithm

Nov 16th, 2021 - Neonatal jaundice is common and mostly transient without need for intervention. To identify infants at risk of bilirubin toxicity, bilirubin is measured several times after birth and before discharge home. As the peak bilirubin concentrations are ...

Screening and Follow-up Study of Neonatal Jaundice Based on Mobile Network

Nov 1st, 2021 - This is a prospective cohort study of healthy term and near-term infants. The mobile network screening and follow-up of neonatal jaundice consists of two parts, one is the screening and follow-up program for healthy neonatal jaundice by using on p...

Tactile and Kinaesthetic Stimulation in Neonates With Hyperbilirubinaemia

Oct 14th, 2021 - Hyperbilirubinemia is the commonest problem seen in neonates, owing to severe complications in lifetime. The study design of the study is pretest - posttest experimental design. Convenience Sampling will be used for recruiting the neonates. In stu...

Timing of Umbilical Cord Clamping in Term Cesarean Deliveries

Aug 3rd, 2021 - Late clamping of the umbilical cord has been shown to have positive effects such as higher neonatal hemoglobin level, higher iron stores in the newborn around three to six months, and better neurological development. In 2017, American College of O...

Biomarker for Gilbert Disease (BioGilbert)

May 13th, 2021 - Gilbert syndrome is a mild genetic liver disorder in which the body cannot properly process bilirubin, a yellowish waste product that is formed when old or worn out red blood cells are broken down (hemolysis). It is inherited as an autosomal reces...

see more →

News  110 results

Enasidenib/Azacitidine Combo Shows Early, Promising Activity in IDH2-Mutant AML

Nov 23rd, 2021 - The combination of enasidenib (Idhifa) plus azacitidine (Onureg) was well tolerated and induced significantly improved response rates compared with azacitidine alone in patients with newly diagnosed, IDH2-mutant acute myeloid leukemia (AML), accor...

Chemotherapy With FOLFOX Superior to TACE in Liver Cancer

Nov 11th, 2021 - Hepatic arterial infusion chemotherapy (HAIC) with FOLFOX led to superior patient outcomes and less toxicity than standard of care transarterial chemoembolization (TACE) for patients with large, unresectable hepatocellular carcinoma (HCC), a rando...

Arterial Chemo Tops Chemoembolization for Large Liver Tumors

Oct 22nd, 2021 - Patients with unresectable large-volume liver cancer lived significantly longer when treated with hepatic-artery infusion chemotherapy (HAIC) than with transarterial chemoembolization (TACE), a randomized trial from China showed. Median overall su...

Expert Recaps Advances in AML

Oct 6th, 2021 - Rami S. Komrokji, MD Now that physicians have access to novel therapies for patients with acute myeloid leukemia (AML) following a 30-year gap in therapeutic development, physicians must now aim to understand their optimal placement in treatment,...

Global Real-World Data Establish TheraSphere Y-90 as Optimal Choice for HCC

Oct 6th, 2021 - TheraSphere Y-90 glass microspheres offer a precision medicine technique aimed at delivering high-dose radiation directly to tumors. Most recently, investigators examined data from the retrospective TARGET study (NCT03295006), which aimed to provi...

see more →

Patient Education  2 results see all →